Evaluation of Clinical and Radiological Outcomes Following the Treatment of Periodontal Intraosseous Defects Using Autogenous Tooth-derived Graft or Autogenous Bone Graft With Enamel Matrix Derivatives. A 12-month Randomized Controlled Clinical Trial.

Launched by SEMMELWEIS UNIVERSITY · May 19, 2025

Keywords

ClinConnect Summary

This randomized controlled clinical trial investigates the regenerative efficacy of autogenous tooth-derived graft material (ATB) in comparison with autogenous bone graft (ABG) in the treatment of periodontal intraosseous defects. Enamel matrix derivative (EMD) is applied to all defects in both treatment groups as part of the regenerative procedure, and a standardized, minimally invasive flap approach is used for defect access.

The regenerative management of intrabony periodontal defects often involves the application of biologically active materials in conjunction with particulate grafts,...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patients diagnosed with chronic periodontitis
• • Both male and female participants
• • Patients with less than 25% plaque score (FMPS: Full Mouth Plaque Score) and bleeding index (FMBS: Full Mouth Bleeding Score) after non-surgical periodontal therapy
• • Good patient compliance (maintains good oral hygiene and is willing to participate in 12-month follow-up)
• • Patients who understand the nature of the study after receiving written information and provide signed informed consent
• • Patients older than 18 years
• • Non-self-contained intraosseous defects (wide (radiological angle \> 37°) and/or one- or two-wall defects) in the maxilla or mandible with a baseline probing depth of ≥ 6 mm
• • The defect has an intraosseous component of ≥ 3 mm
• • The patient has at least one tooth that needs extraction for any reason
• Exclusion Criteria:
• * Patients with systemic conditions such as:
• • Alcoholism Drug addiction Known HIV, HBV, or HCV infection Patients undergoing chemotherapy or radiation therapy Current or past head and neck radiation therapy Untreated insulin-dependent diabetes mellitus Clinically significant osteoporosis or other systemic conditions affecting bone metabolism Clinically significant cardiovascular conditions such as decompensated heart failure, hemodynamically significant heart valve insufficiency, or myocardial infarction within the last 3 months Clinically significant coagulation disorders
• • Previous or current systemic corticosteroid therapy (within 2 months of inclusion): more than 5 mg of prednisolone per day
• • Previous or current bisphosphonate therapy lasting at least 30 days within the past 12 months
• • Long-term antibiotic or anti-inflammatory therapy within the past 4 months
• • Pregnant or breastfeeding women
• • Smoking (\>5 cigarettes/day)
• • Furcation involvement
• • Wisdom teeth